Do you want to join one of the fastest-growing molecular diagnostics companies to help transform prenatal and oncology diagnostics that can affect millions of patient lives?

BillionToOne, one of the top Y Combinator companies with $200M+ in funding from prominent VC firms, has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold. We are the only technology platform that can detect single-gene disorders in an unborn baby from maternal blood and that can accurately quantify tumor DNA changes in cancer patients.

UNITY Screen, our prenatal test, continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy products, which will transform oncology care.